Marble Harbor Investment Counsel LLC Purchases 26,200 Shares of Pfizer Inc. $PFE

Marble Harbor Investment Counsel LLC raised its position in Pfizer Inc. (NYSE:PFE) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 393,121 shares of the biopharmaceutical company’s stock after acquiring an additional 26,200 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $10,017,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in PFE. Curio Wealth LLC boosted its holdings in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter worth approximately $32,000. Finally, Evelyn Partners Asset Management Ltd purchased a new stake in Pfizer during the 2nd quarter worth approximately $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE PFE opened at $27.37 on Wednesday. The firm has a market capitalization of $155.62 billion, a P/E ratio of 20.13 and a beta of 0.47. The stock has a 50-day simple moving average of $25.88 and a two-hundred day simple moving average of $25.26. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period last year, the company earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. UBS Group began coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Bank of America cut their price objective on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Finally, Morgan Stanley decreased their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.